NEWS & EVENTS
EWMA 2020
November 2020
Prof. Nikolaos Tentolouris from Laikο General Hospital of Athens, Greece, will present a poster titled “Recombinant human collagen-based flowable matrix for chronic wound management: a case study series”.
EWMA 2020 Virtual
Vergenix™FG now available in Ukraine
October 2020
Patients in Ukraine will now have access to Vergenix™FG.
For more details, contact us
New Vergenix™FG clinical results now published
July 2020
Study by Iacopi E et al from the University Hospital in Pisa, Italy shows increased healing rate and shortened healing time in patients with post-surgical diabetic foot wounds treated with Vergenix™ FG.
Full abstract
MEDICA 2019
November 2019
CollPlant exhibits at the MEDICA trade-fair, 18-21 November 2019, in Düsseldorf, Germany. Visit us at hall 16/ M25.
Medica website
Dr. Eyal Shapira presents Vergenix™FG results and wins the presenter prize at the EWMA 2019
July 2019
Dr. Eyal Shapira from the department of Plastic Surgery, Assaf Harofeh Medical Center, Israel, wins the first time international presenter prize at the EWMA 2019 conference for his oral presentation on the results from a clinical study conducted with Vergenix™FG .
EWMA awards
CollPlant signs a distribution agreement with Green Leaf Pharma
June 2019
CollPlant is pleased to announce that a distribution agreement for Russia and Ukraine has been executed with Green Leaf Pharma, а dynamically growing company specializing in bio-pharmaceutical development and medical device distribution.
Green Leaf Pharma website
Presenting at the EWMA 2019 conference
June 2019
CollPlant to exhibit at the 29th Conference of the European Wound Management Association (EWMA), 5-7 June 2019 in Gothenburg, Sweden. Dr. Eyal Shapira from the department of Plastic Surgery, Assaf Harofeh Medical Center, Israel, to present results from a clinical study conducted with Vergenix™FG. Visit us at booth B09:09.
EWMA 2019 website
Vergenix™FG clinical results published in WOUNDS journal
March 2019
Study published in Wounds Journal shows remarkable wound closure performance with Vergenix™FG in the treatment of chronic wounds with a 94% median wound area reduction.
Full publication